Share Name Share Symbol Market Type Share ISIN Share Description
Marlowe Plc LSE:MRL London Ordinary Share GB00BD8SLV43 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.00 0.26% 784.00 780.00 788.00 784.00 782.00 782.00 34,348 12:34:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 128.5 2.0 3.8 206.3 605

Marlowe Share Discussion Threads

Showing 2726 to 2747 of 2750 messages
Chat Pages: 110  109  108  107  106  105  104  103  102  101  100  99  Older
Ahead of consensus, looks like things are going to plan and this continues its steady climb. More bolt on acquisitions today too.
dr biotech
Under the radar share this one. Scsw like it too
Marlowe growth plans to drive shares, says Berenberg Security systems provider Marlowe has set out ‘highly ambitious’ growth targets that Berenberg says could deliver serious upside. Analyst Calum Battersby reiterated his ‘buy’ recommendation and increased the target price from 660p to 900p. The company has announced targets over the next 3 years, including hitting £500m of revenue and £100m of earnings to be achieved ‘through a combination of 7% of organic growth per annum, 20% margins, 90% cash conversion and continuation of the group’s existing M&A strategy’, according to Battersby. ‘While clearly an aggressive target, we believe this can be achieved, given the company’s track record to date, and the scale of opportunities that already exist in its various end-markets,’ he said.
Decent enough update, higher targets and trading towards the top end of forecasts. Always going to be a relatively slow burner
dr biotech
20 November 2020 Completion of Refinancing Marlowe plc announces that has signed a new, enlarged revolving credit facility with HSBC UK Bank PLC and National Westminster Bank PLC. The new facility replaces the Group's existing GBP45 million facility and comprises a three-year, £70m revolving credit facility and an additional accordion facility of £20m. The enlarged debt facility will provide further resources to support the Group's ongoing targeted acquisition strategy. The Group will publish Half Year results for the period ended 30 September 2020 on 3 December 2020.
Another brick in the wall ! Acquisition of Black & Banton Occupational and Physical Health Limited Marlowe plc ("Marlowe" or the "Group"), the specialist services group focused on developing companies which assure safety and regulatory compliance, announces that it has acquired Black & Banton Occupational and Physical Health Limited ("Black & Banton") for an initial consideration of £1.1m. Black & Banton, established in 2001, is headquartered in Gateshead, Tyne and Wear, and provides occupational health services to businesses in the North of England and Scotland. For the year ended 30 April 2020, Black & Banton generated profit before tax of £0.4m on revenues of £1.7m. Net assets at 30 April 2020 were £0.9m. The total enterprise value of up to £1.5mn includes a contingent cash earn-out of up to £0.4m. The acquisition will be funded from Marlowe's existing cash resources.
Investor's Champion comments "The consideration paid for acquisitions is clearly not the true cost given the significant subsequent restructuring costs incurred, with £6.7m in 2020."
(Edit) paid 60m for a company that make 4.4m. Not a bargain, but seems a strategic fit. Placing at current share price always a sign of confidence. I
dr biotech
28 October 2020 Marlowe plc Acquisition of Ellis Whittam (Holdings) Limited Marlowe plc, the specialist services group focused on developing companies which assure safety and regulatory compliance, announces that it has entered into a conditional agreement to acquire Ellis Whittam (Holdings) Ltd (together with its subsidiaries) for consideration of £59m on a cash-free, debt-free basis. Founded in 2004, Ellis Whittam is one of the UK's leading providers of outsourced Employment Law, HR and Health & Safety services. The company provides its services via a fixed-fee subscription model to over 3,300 organisations across the UK. It is headquartered in Chester, with offices in Glasgow and London, and employs approximately 180 staff, more than half of whom are health & safety consultants, employment lawyers and HR compliance advisors. Ellis Whittam's subscription-based advisory services help employers across the UK remain compliant with evolving employment law and health & safety legislation. The Group also announces a proposed placing to raise gross proceeds of up to £30m through the issue of up to 5,441,376 new ordinary shares of 50 pence each (the "Placing Shares") at 547p per share (the "Placing Price") to new and existing investors (the "Placing"). The Placing will be conducted by way of an accelerated bookbuild process which will be launched immediately in accordance with the terms and conditions set out in the Appendix to this Announcement. ........................................................................................................................................... . 29 October 2020 Marlowe plc Results of the Placing Further to the announcement of 28 October 2020 of the acquisition of Ellis Whittam and a proposed placing, Marlowe announces that it has successfully raised approximately £30m before expenses under the Placing, which was oversubscribed. The Placing Price of 547p per share represents a nil discount to the closing price on 28 October 2020. A total of 5,441,376 Placing Shares were placed with institutional investors, conditional on Admission. Pursuant to the Placing, the Group has raised net proceeds of approximately £29m after expenses. The issue of the Placing Shares is not subject to shareholder approval. Application has been made for the 5,441,376 Placing Shares to be admitted to trading on AIM, and it is expected that Admission will occur at 8.00 a.m. on or around 3 November 2020. Therefore, following Admission of the Placing Shares, the total number of Ordinary Shares with voting rights in the Group will be 60,266,796, which may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Group under the FCA's Disclosure Guidance and Transparency Rules.
Great - many thanks for confirming
Small company share watch. It’s a decent journal.
dr biotech
Hi, which tip sheet were they mentioned on?
I bought these on the back of a share tip sheet. Its interesting to see the number of trades today so far is 34. Last week there were typically between 5-15 trades a day, gives an idea how many of us are reading and following this publication. I guess you'd have to look after a few days for a real figure. But I did notice this was marked up on opening to make sure we all paid a few quid extra.
dr biotech
They are certainly busy hoovering up smaller co’s. I’d like to know how much management time each acquisition gets. I’m in from this morning.
dr biotech
Thanks for starting thread - based on ADVFN data p/e looks vry much on the high side (imo) but need to dig a lot deeper.
This company employs a similar business strategy to Premier Technical Services Group (PTSG). They were a very profitable former investment for me that was subsequently bought out for 210p in June last year, generating a capital gain of over 100%. This company has a strong growth potential in a very fragmented market providing they efficiently and effectively manage their M & A strategy.
Marlowe delivers compliance services across four individual and integrated divisions. Health & Safety, Fire Safety & Security, Air Testing & Quality and Water Treatment & Hygiene, utilising their own proprietary software platform. The business has developed using a buy & build strategy to establish a one-stop facility, which can be used by single site SME's as well as large multi-site companies. Marlowe was founded in mid-2015 by current CEO Alex Dacre and through organic growth and acquisition, it has become a leading specialist services group that provides safety and regulatory compliance. The company was originally formed out of a cash shell and backed by Lord Ashcroft. It is led by a Board of Directors with considerable experience in running large quoted and private businesses in the support services sector. It was admitted to AIM in April 2016. Marlowe operates in specialist, regulated markets and they provide services that are non-discretionary and generally insulated from changes in trends or the economy. The future growth of the business is underpinned by long-term drivers such as population growth, insurance requirements, reputational risk, urbanisation, increasing safety standards and increased digitalisation driving the need for more complex building systems and the consequences that this has for both maintenance & certification. Their service facilities address the increasingly broad and stringent health, safety and environmental regulations and the legal requirements to ensure that they are adopted and implemented. They operate in fragmented markets which can best be served by sourcing complementary bolt-on acquisitions that can be integrated, resulting in increased efficiency, cost-savings, broader capabilities and an expanding market share based on new revenue synergies that become available through effective intercompany collaboration. Their services are non-cyclical and they annually schedule over 1m service visits to audit, test, inspect, maintain & certify tens of thousands of properties and assets. Major Shareholders as at 30 September 2020 Lord Michael Ashcroft: 11,877,361. 23.54% Alex Dacre (CEO): 3,521,334. 6.97% Danske Capital Mgt: 3,116,184.00. 6.77% Canaccord Genuity Wealth Mgt: 2,499,783. 4.95% Royce & Associates: 1,872,506. 3.71% Majedie Asset Management: 1,421,095. 2.81% Columbia Threadneedle Investments: 1,388,011. 2.75% Total number of shares in issue: 50,455,989
This chart is looking very interesting. After a dramatic fall in March to 318 it made a dramatic move back up to 510 in May and has now retraced and established a floor at 470. Looks like it is forming the right hand handle of the cup now and I expect a move back to 510 and above in the next couple of weeks. Depending on the FY results and update on trading, this could challenge ATH of 570 from Sept 2018.
well, that's a nice 16.7% rise in two weeks since my last post. market waking up to results towards end of June.
Year end results due June (March year end). Market cap currently 145.6m. 2019 forecast 10.6m adjusted EDITDA, 2020 forecast 14m adjusted EBITDA. On a 20 multiple share price should be 5.19 now and 6.86 next year. On a 15 multiple 3.89 and 5.14 next year. I reckon this year may come in at 12m adjusted EBITDA which on a 15 or 20 multiple is an share price of 4.41 or 5.88. Whichever, today's price of 3.57 is significantly undervaluing Marlowe
Half Year report due in the next 2-3 weeks. Pretty big re-trace from recent highs now... 400p could well be a good entry point here now if it holds.
Does anyone have any thoughts as to whether anything can be gleaned from LSC’s interim results? LSC seems a bit more internationally diversified but there wa a hint of a warning at the end of the report.
Chat Pages: 110  109  108  107  106  105  104  103  102  101  100  99  Older
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210613 13:20:24